{"id":"marketed-rabies-vaccine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site pain, erythema, or swelling"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Myalgia or fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabies vaccines work by introducing inactivated or attenuated rabies virus antigen to trigger both humoral (antibody) and cell-mediated immune responses. This priming allows the vaccinated individual's immune system to rapidly recognize and neutralize rabies virus if exposed, preventing the virus from reaching the central nervous system where it causes fatal encephalitis.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:09.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rabies post-exposure prophylaxis (PEP) in individuals exposed to potentially rabid animals"},{"name":"Rabies pre-exposure prophylaxis (PrEP) in high-risk populations (veterinarians, laboratory workers, travelers to endemic regions)"}]},"trialDetails":[{"nctId":"NCT07357545","phase":"PHASE3","title":"Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-08-27","conditions":"Rabies (Healthy Volunteers)","enrollment":2040},{"nctId":"NCT07055893","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies (Healthy Volunteers)","enrollment":390},{"nctId":"NCT07055880","phase":"PHASE2","title":"Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-07-28","conditions":"Rabies","enrollment":120},{"nctId":"NCT07055295","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies","enrollment":390},{"nctId":"NCT00893906","phase":"PHASE4","title":"Inactivated Influenza Vaccine Effectiveness in Tropical Africa","status":"COMPLETED","sponsor":"PATH","startDate":"2009-05","conditions":"Influenza","enrollment":10000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Marketed rabies vaccine","genericName":"Marketed rabies vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure. Used for Rabies post-exposure prophylaxis (PEP) in individuals exposed to potentially rabid animals, Rabies pre-exposure prophylaxis (PrEP) in high-risk populations (veterinarians, laboratory workers, travelers to endemic regions).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}